LIDDS AB (publ) (LIDDS.ST)
SEK 0.03
(-15.5%)
SEK 0.03
(-15.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -13.51 Million SEK | -968.99% |
| 2022 | -1.26 Million SEK | 96.28% |
| 2021 | -34 Million SEK | 5.74% |
| 2020 | -36.07 Million SEK | -377.05% |
| 2019 | -7.56 Million SEK | 71.07% |
| 2018 | -26.13 Million SEK | -70.99% |
| 2017 | -15.28 Million SEK | 18.17% |
| 2016 | -18.68 Million SEK | -20.71% |
| 2015 | -15.47 Million SEK | 13.76% |
| 2014 | -17.94 Million SEK | -331.49% |
| 2013 | -4.15 Million SEK | 3.17% |
| 2012 | -4.29 Million SEK | 63.92% |
| 2011 | -11.9 Million SEK | -63.5% |
| 2010 | -7.28 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -8 Million SEK | 26.84% |
| 2024 Q1 | -10.94 Million SEK | 18.98% |
| 2023 Q2 | -22.7 Million SEK | 23.85% |
| 2023 Q3 | -17.09 Million SEK | 24.72% |
| 2023 Q4 | -13.51 Million SEK | 20.95% |
| 2023 FY | -13.51 Million SEK | -968.99% |
| 2023 Q1 | -29.82 Million SEK | -2259.26% |
| 2022 Q1 | -27.45 Million SEK | 19.26% |
| 2022 Q4 | -1.26 Million SEK | 91.52% |
| 2022 FY | -1.26 Million SEK | 96.28% |
| 2022 Q2 | -19.71 Million SEK | 28.19% |
| 2022 Q3 | -14.9 Million SEK | 24.38% |
| 2021 Q3 | -44.25 Million SEK | 18.2% |
| 2021 Q2 | -54.09 Million SEK | -132.06% |
| 2021 FY | -34 Million SEK | 5.74% |
| 2021 Q1 | -23.31 Million SEK | 35.38% |
| 2021 Q4 | -34 Million SEK | 23.16% |
| 2020 FY | -36.07 Million SEK | -377.05% |
| 2020 Q1 | -8.51 Million SEK | -12.62% |
| 2020 Q2 | -3.32 Million SEK | 61.01% |
| 2020 Q3 | -47.23 Million SEK | -1322.55% |
| 2020 Q4 | -36.07 Million SEK | 23.64% |
| 2019 Q2 | -16.86 Million SEK | 7.43% |
| 2019 Q3 | -9.55 Million SEK | 43.35% |
| 2019 Q1 | -18.21 Million SEK | 30.31% |
| 2019 Q4 | -7.56 Million SEK | 20.84% |
| 2019 FY | -7.56 Million SEK | 71.07% |
| 2018 Q1 | -22.21 Million SEK | -45.35% |
| 2018 FY | -26.13 Million SEK | -70.99% |
| 2018 Q4 | -26.13 Million SEK | 30.36% |
| 2018 Q3 | -37.53 Million SEK | -4.18% |
| 2018 Q2 | -36.02 Million SEK | -62.14% |
| 2017 Q1 | -9.43 Million SEK | 49.51% |
| 2017 Q2 | -9.03 Million SEK | 4.23% |
| 2017 Q4 | -15.28 Million SEK | 22.39% |
| 2017 Q3 | -19.69 Million SEK | -118.06% |
| 2017 FY | -15.28 Million SEK | 18.17% |
| 2016 Q3 | -23.94 Million SEK | -279.78% |
| 2016 Q2 | -6.3 Million SEK | 44.58% |
| 2016 Q1 | -11.37 Million SEK | 26.49% |
| 2016 FY | -18.68 Million SEK | -20.71% |
| 2016 Q4 | -18.68 Million SEK | 21.98% |
| 2015 Q2 | -9.21 Million SEK | 33.47% |
| 2015 Q4 | -15.47 Million SEK | -116.17% |
| 2015 FY | -15.47 Million SEK | 13.76% |
| 2015 Q1 | -13.84 Million SEK | 22.82% |
| 2015 Q3 | -7.15 Million SEK | 22.3% |
| 2014 Q1 | -1.49 Million SEK | 64.0% |
| 2014 Q2 | -911 Thousand SEK | 39.14% |
| 2014 Q3 | -23.78 Million SEK | -2511.2% |
| 2014 Q4 | -17.94 Million SEK | 24.57% |
| 2014 FY | -17.94 Million SEK | -331.49% |
| 2013 Q1 | 4.29 Million SEK | 0.0% |
| 2013 Q4 | -4.15 Million SEK | 0.0% |
| 2013 FY | -4.15 Million SEK | 3.17% |
| 2012 FY | -4.29 Million SEK | 63.92% |
| 2011 FY | -11.9 Million SEK | -63.5% |
| 2010 FY | -7.28 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 350.222% |
| AcouSort AB (publ) | -23.98 Million SEK | 43.667% |
| Active Biotech AB (publ) | -33.2 Million SEK | 59.301% |
| Alzinova AB (publ) | -21.22 Million SEK | 36.342% |
| Amniotics AB (publ) | -5.63 Million SEK | -139.915% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -525.266% |
| BioArctic AB (publ) | -606.58 Million SEK | 97.772% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.841% |
| Cantargia AB (publ) | -139.74 Million SEK | 90.331% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1363.922% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 54.014% |
| Genovis AB (publ.) | -43.94 Million SEK | 69.25% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 83.865% |
| Mendus AB (publ) | -96.29 Million SEK | 85.968% |
| Kancera AB (publ) | -45.69 Million SEK | 70.428% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 83.562% |
| Lipum AB (publ) | -8.46 Million SEK | -59.622% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 57.678% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 125.388% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 29.108% |
| NextCell Pharma AB | -46.79 Million SEK | 71.122% |
| OncoZenge AB (publ) | -12.62 Million SEK | -7.009% |
| Saniona AB (publ) | 40.44 Million SEK | 133.407% |
| Simris Alg AB (publ) | 85.07 Million SEK | 115.882% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 95.95% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 108.136% |
| Xintela AB (publ) | -7.8 Million SEK | -73.031% |
| Ziccum AB (publ) | -2.13 Million SEK | -532.288% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 90.219% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 89.566% |
| CombiGene AB (publ) | -101.44 Million SEK | 86.68% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 83.539% |
| Intervacc AB (publ) | -88.16 Million SEK | 84.673% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 72.987% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 72.94% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 165.88% |
| Corline Biomedical AB | -17.01 Million SEK | 20.574% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 83.865% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 65.69% |
| Aptahem AB (publ) | 2.9 Million SEK | 564.547% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 95.894% |
| Fluicell AB (publ) | -2.76 Million SEK | -389.034% |
| Biovica International AB (publ) | -58.73 Million SEK | 76.996% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 70.117% |
| Abliva AB (publ) | -57.24 Million SEK | 76.394% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 93.06% |
| 2cureX AB (publ) | -13.4 Million SEK | -0.813% |
| I-Tech AB | -83.26 Million SEK | 83.772% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 110.031% |
| Cyxone AB (publ) | -16.67 Million SEK | 18.944% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 75.822% |
| Biosergen AB | -1.88 Million SEK | -617.578% |
| Nanologica AB (publ) | -9.38 Million SEK | -43.928% |
| SynAct Pharma AB | -61.75 Million SEK | 78.121% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 36.904% |
| BioInvent International AB (publ) | -236.3 Million SEK | 94.282% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -2.138% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 79.809% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -160.803% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 35.017% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -354.643% |